|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...2930313233343536373839...4950» |
- Enrollment closed, IO biomarker: Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission (clinicaltrials.gov) - Jun 23, 2013
P=N/A, N=3200, Active, not recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting --> Active, not recruiting
- ||||||| Trial completion, Combination therapy: Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. (clinicaltrials.gov) - Jun 20, 2013
P3, N=180, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial termination, Adherence: Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy (clinicaltrials.gov) - Jun 19, 2013
P1, N=7, Terminated, Sponsor: RAND
Active, not recruiting --> Completed Recruiting --> Terminated; Inability to recruit enough eligible participants at study site.
- Enrollment change, Adherence: Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy (clinicaltrials.gov) - Jun 19, 2013
P1, N=7, Terminated, Sponsor: RAND
Recruiting --> Terminated; Inability to recruit enough eligible participants at study site. N=70 --> 7
- Trial withdrawal: A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients (clinicaltrials.gov) - Jun 17, 2013
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
N=70 --> 7 Not yet recruiting --> Withdrawn
- | pritelivir (AIC316) / AiCuris
Trial termination: Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes (clinicaltrials.gov) - Jun 17, 2013
P2, N=91, Terminated, Sponsor: AiCuris GmbH & Co.KG
Not yet recruiting --> Withdrawn Suspended --> Terminated
- Enrollment change: A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients (clinicaltrials.gov) - Jun 17, 2013
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
Suspended --> Terminated N=50 --> 0
- Enrollment change, Adherence: Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study) (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=240, Completed, Sponsor: Massachusetts General Hospital
N=50 --> 0 N=200 --> 240
- Trial completion, Adherence: Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study) (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=240, Completed, Sponsor: Massachusetts General Hospital
N=200 --> 240 Active, not recruiting --> Completed
- Trial completion, Adherence: Adherence Intervention for People With Low-literacy (clinicaltrials.gov) - Jun 13, 2013
P2, N=450, Completed, Sponsor: University of Connecticut
Active, not recruiting --> Completed Active, not recruiting --> Completed
- HIV MAG pDNA vaccine / Profectus, National Institute of Allergy and Infectious Diseases
Trial completion: Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers (clinicaltrials.gov) - Jun 11, 2013
P1, N=75, Completed, Sponsor: International AIDS Vaccine Initiative
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Trial completion: Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects (clinicaltrials.gov) - Jun 11, 2013
P2, N=123, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zidovudine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults (clinicaltrials.gov) - Jun 6, 2013
P=N/A, N=529, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=46, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed N=128 --> 46
- Trial completion: Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=46, Completed, Sponsor: Indiana University
N=128 --> 46 Active, not recruiting --> Completed
- ||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - May 29, 2013
P=N/A, N=400, Recruiting, Sponsor: Gilead Sciences
- ||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical: A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication (clinicaltrials.gov) - May 29, 2013
P=N/A, N=400, Recruiting, Sponsor: Gilead Sciences
- | Selzentry (maraviroc) / ViiV Healthcare
New P4 trial: Switching Undetectables to Selzentry (clinicaltrials.gov) - May 29, 2013
P4, N=30, Recruiting, Sponsor: St. Hope Foundation
- methamphetamine / Generic mfg.
Trial completion, Adherence: Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE) (clinicaltrials.gov) - May 29, 2013
P=N/A, N=210, Completed, Sponsor: Hunter College
Active, not recruiting --> Completed Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Enrollment change, IO biomarker: Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients (clinicaltrials.gov) - May 28, 2013
P=N/A, N=18, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed N=24 --> 18
- Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Enrollment open: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - May 28, 2013
P2, N=471, Recruiting, Sponsor: AIDS Clinical Trials Group
N=24 --> 18 Not yet recruiting --> Recruiting
- ||||| darunavir/ritonavir / Generic mfg.
Trial initiation date: Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (clinicaltrials.gov) - May 27, 2013
P3, N=316, Completed, Sponsor: Janssen-Cilag G.m.b.H
Not yet recruiting --> Recruiting Initiation date: Jan 1999 --> Nov 2011
- Enrollment change: Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability (clinicaltrials.gov) - May 27, 2013
P=N/A, N=1235, Completed, Sponsor: Brigham and Women's Hospital
Initiation date: Jan 1999 --> Nov 2011 N=1020 --> 1235
- Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial initiation date: Effects of Intensive cART During Acute/Early HIV Infection (clinicaltrials.gov) - May 26, 2013
P2/3, N=32, Active, not recruiting, Sponsor: University of Toronto
N=1020 --> 1235 Initiation date: Sep 2010 --> Nov 2011
- Enrollment open: IDEAL-Study: Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (clinicaltrials.gov) - May 26, 2013
P4, N=210, Recruiting, Sponsor: Universit
Initiation date: Sep 2010 --> Nov 2011 Not yet recruiting --> Recruiting
- Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Enrollment closed: Effects of Intensive cART During Acute/Early HIV Infection (clinicaltrials.gov) - May 26, 2013
P2/3, N=32, Active, not recruiting, Sponsor: University of Toronto
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date, Combination therapy: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects (clinicaltrials.gov) - May 22, 2013
P3, N=13, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Active, not recruiting Initiation date: Apr 2011 --> Jan 2012
- Enrollment change: Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study (clinicaltrials.gov) - May 22, 2013
P4, N=33, Completed, Sponsor: Fundacio Lluita Contra la SIDA
Initiation date: Apr 2011 --> Jan 2012 N=45 --> 33
- MVA/HIV62B vaccine / National Institute of Allergy and Infectious Diseases
Enrollment closed: A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART (clinicaltrials.gov) - May 22, 2013
P1, N=9, Active, not recruiting, Sponsor: GeoVax, Inc.
N=45 --> 33 Recruiting --> Active, not recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: PINT: The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (clinicaltrials.gov) - May 22, 2013
P=N/A, N=16, Completed, Sponsor: Kirby Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Mycobutin (rifabutin) / Pfizer, Lupin
Trial termination: Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults (clinicaltrials.gov) - May 21, 2013
P2, N=12, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; Poor enrollment
- Clinical: Evaluating a Microfinance Intervention for High Risk Women in Mongolia (clinicaltrials.gov) - May 21, 2013
P=N/A, N=107, Active, not recruiting, Sponsor: Columbia University
- | Eyevinal (ibudilast) / MediciNova
New P2 trial: IBUD ph II: Trial of Ibudilast for Methamphetamine Dependence (clinicaltrials.gov) - May 21, 2013
P2, N=140, Recruiting, Sponsor: University of California, Los Angeles
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment open: First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers (clinicaltrials.gov) - May 21, 2013
P1, N=21, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
Enrolling by invitation --> Terminated; Poor enrollment Not yet recruiting --> Recruiting
- || Isentress (raltegravir) / Merck (MSD)
Enrollment change, Combination therapy: A Study to Assess the Efficacy of Raltegravir (Isentress (clinicaltrials.gov) - May 20, 2013
P=N/A, N=443, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=265 --> 443
- Enrollment closed: Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485) (clinicaltrials.gov) - May 20, 2013
P2, N=650, Active, not recruiting, Sponsor: Aeras
N=265 --> 443 Recruiting --> Active, not recruiting
- lopinavir/ritonavir / Generic mfg.
Trial termination, Adherence: The Mochudi Prevention Project ART Protocol (clinicaltrials.gov) - May 16, 2013
P=N/A, N=11, Terminated, Sponsor: Harvard School of Public Health
Recruiting --> Active, not recruiting Not yet recruiting --> Terminated; Low Accrual.
- lopinavir/ritonavir / Generic mfg.
Enrollment change, Adherence: The Mochudi Prevention Project ART Protocol (clinicaltrials.gov) - May 16, 2013
P=N/A, N=11, Terminated, Sponsor: Harvard School of Public Health
Not yet recruiting --> Terminated; Low Accrual. N=235 --> 11
- | Trial completion: Observational Study of Blood Treated With Cytolin (clinicaltrials.gov) - May 16, 2013
P=N/A, N=20, Completed, Sponsor: CytoDyn, Inc.
N=235 --> 11 Active, not recruiting --> Completed
- Trial completion: A School-Based HIV/STD Prevention Program to Reduce Risky Sexual Behaviors Among Adolescents in Liberia (clinicaltrials.gov) - May 16, 2013
P=N/A, N=866, Completed, Sponsor: Pacific Institute for Research and Evaluation
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination: Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV (clinicaltrials.gov) - May 15, 2013
P=N/A, N=20, Terminated, Sponsor: Rockefeller University
Recruiting --> Completed Recruiting --> Terminated; Investigator left Rockefeller University
- cenicriviroc (TBR-652) / Takeda, AbbVie
Enrollment change: Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors (clinicaltrials.gov) - May 15, 2013
P2b, N=5, Terminated, Sponsor: University of California, San Francisco
Recruiting --> Terminated; Investigator left Rockefeller University N=15 --> 5
- Enrollment open: Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients (clinicaltrials.gov) - May 15, 2013
P=N/A, N=600, Recruiting, Sponsor: University of California, San Francisco
N=15 --> 5 Not yet recruiting --> Recruiting
- entecavir / Generic mfg.
Enrollment change: Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection (clinicaltrials.gov) - May 14, 2013
P4, N=10, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=24 --> 10
- Trial initiation date: Pilot Study of Diflunisal in HIV-infected Adults (clinicaltrials.gov) - May 12, 2013
P4, N=20, Recruiting, Sponsor: University of British Columbia
N=24 --> 10 Initiation date: Aug 2012 --> Mar 2013
- Trial completion: HIV Diagnosis in Hospitalized Malawian Infants (clinicaltrials.gov) - May 12, 2013
P=N/A, N=300, Completed, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Aug 2012 --> Mar 2013 Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Enrollment change: ENCORE1-CNS;NCHECR-ENCORE1-CNS: The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1 (clinicaltrials.gov) - May 9, 2013
P3, N=32, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed N=40 --> 32
- ||||| darunavir/ritonavir / Generic mfg.
Enrollment closed, Combination therapy, Monotherapy: A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment (clinicaltrials.gov) - May 9, 2013
P3, N=274, Active, not recruiting, Sponsor: Janssen-Cilag International NV
N=40 --> 32 Recruiting --> Active, not recruiting
- efavirenz / Generic mfg.
Trial completion: ENCORE1-CNS;NCHECR-ENCORE1-CNS: The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1 (clinicaltrials.gov) - May 9, 2013
P3, N=32, Completed, Sponsor: Kirby Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- efavirenz / Generic mfg.
Trial completion: The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK) (clinicaltrials.gov) - May 9, 2013
P3, N=40, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed